379 related articles for article (PubMed ID: 8973882)
1. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
[TBL] [Abstract][Full Text] [Related]
2. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus.
Karsidag S; Morali S; Sargin M; Salman S; Karsidag K; Us O
Diabetes Res Clin Pract; 2005 Mar; 67(3):211-9. PubMed ID: 15713353
[TBL] [Abstract][Full Text] [Related]
3. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
Airey M; Bennett C; Nicolucci A; Williams R
Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.
Nicolucci A; Carinci F; Graepel JG; Hohman TC; Ferris F; Lachin JM
Diabetes Care; 1996 Oct; 19(10):1091-6. PubMed ID: 8886554
[TBL] [Abstract][Full Text] [Related]
5. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
Airey M; Bennett C; Nicolucci A; Williams R
Cochrane Database Syst Rev; 2000; 1996(2):CD002182. PubMed ID: 10796870
[TBL] [Abstract][Full Text] [Related]
6. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Bril V; Buchanan RA
Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
Valensi P; Attali JR; Gagant S
Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589
[TBL] [Abstract][Full Text] [Related]
9. Medial plantar and dorsal sural nerve conduction studies increase the sensitivity in the detection of neuropathy in diabetic patients.
Uluc K; Isak B; Borucu D; Temucin CM; Cetinkaya Y; Koytak PK; Tanridag T; Us O
Clin Neurophysiol; 2008 Apr; 119(4):880-5. PubMed ID: 18291716
[TBL] [Abstract][Full Text] [Related]
10. Pulse pressure is independently associated with sensorimotor peripheral neuropathy in patients with type 2 diabetes.
Jarmuzewska EA; Mangoni AA
J Intern Med; 2005 Jul; 258(1):38-44. PubMed ID: 15953131
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of polyneuropathy severity in chronic renal failure patients on continuous ambulatory peritoneal dialysis or on maintenance hemodialysis].
Janda K; Stompór T; Gryz E; Szczudlik A; Drozdz M; Kraśniak A; Sułowicz W
Przegl Lek; 2007; 64(6):423-30. PubMed ID: 18159852
[TBL] [Abstract][Full Text] [Related]
12. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
13. Neuropathy patterns differ in patients with diabetic complications.
Kiziltan ME; Benbir G
Electromyogr Clin Neurophysiol; 2008; 48(8):351-7. PubMed ID: 19097475
[TBL] [Abstract][Full Text] [Related]
14. Diabetic neuropathy: a clinical, laboratory and electrodiagnostic study.
Halar EM; Graf RJ; Halter JB; Brozovich FV; Soine TL
Arch Phys Med Rehabil; 1982 Jul; 63(7):298-303. PubMed ID: 7092528
[TBL] [Abstract][Full Text] [Related]
15. Diabetic peripheral neuropathy: a correlation of nerve conduction studies and clinical findings.
Braddom RL; Hollis JB; Castell DO
Arch Phys Med Rehabil; 1977 Jul; 58(7):308-13. PubMed ID: 880006
[TBL] [Abstract][Full Text] [Related]
16. Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients.
Kassem HS; Azar ST; Zantout MS; Sawaya RA
Neuro Endocrinol Lett; 2005 Dec; 26(6):775-9. PubMed ID: 16380709
[TBL] [Abstract][Full Text] [Related]
17. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
[TBL] [Abstract][Full Text] [Related]
18. Ranirestat for the management of diabetic sensorimotor polyneuropathy.
Bril V; Hirose T; Tomioka S; Buchanan R;
Diabetes Care; 2009 Jul; 32(7):1256-60. PubMed ID: 19366965
[TBL] [Abstract][Full Text] [Related]
19. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
20. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
